RADIOPHARMACEUTICAL COMPLEXES AND COMBINATIONS

PE0013192026A1Pending Publication Date: 2026-07-02BAYER AG +1

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: PE2026001471
Authority / Receiving Office: PE · PE
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-11-05
Filing Date: 2024-11-05
Publication Date: 2026-07-02

Application Information

Patent Timeline

05 Nov 2024

Priority

05 Nov 2024

Application

PE2026001471

02 Jul 2026

Publication

PE0013192026A1

IPC: A61K51/10; A61P35/00; C07K16/28; C07K16/30; C07K16/32; C07K16/40

CPC: A61K51/1096; A61K51/1027; A61K51/1051; C07K16/28; A61P35/00; C07K2317/77; A61K2039/505; C07K16/32

Inventors: FENG Yuan Zeng; CRUCIANI Veronique

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to tissue-directed compounds of formula (I) where [Ac] is a monoclonal antibody or an antigen-binding fragment thereof having binding affinity for HER2, GPC3, CEACAM5, TROP2, GUCY2C, cMet, FolRa, DLL3, Nectin-4, or STEAP1. It also relates to pharmaceutical combinations comprising a tissue-directed compound of formula (I) and an additional pharmaceutical agent. Such combinations are useful in therapy, preferably in the treatment of hyperproliferative diseases such as cancer.

Need to check novelty before this filing date? Find Prior Art